Open Journal Systems

Effect of Compound A Combined with Compound B on Human Hepatoma HepG2 cells

Gang Yan

Abstract

Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. It is also a high
incidence of malignancy in our country. It is difficult to be diagnosed early, and it is easy to relapse and metastasis
after operation. At present, liver cancer is still recognized as the preferred surgical treatment and the main treatment,
but because many patients with liver cancer diagnosis is in the late, lost the chance of surgical treatment and death
within 1 year after diagnosis, surgical resection rate of 30%, the overall 5-year survival rate is only 30% to 40%. For
patients with hepatocellular carcinoma, postoperative recurrence and metastasis are the main factors affecting the
therapeutic effect and prognosis, and there is still no effective treatment for patients with advanced hepatocellular
carcinoma who cannot be operated. Traditional chemotherapy, radiotherapy for poor efficacy of liver cancer, there
is still a lack of effective chemical prevention and treatment of target [1]. Therefore, this study is the mechanism
of compound A combined with compound B on human hepatoma HepG2 cells. In this study, MTT assay was
used to detect the effects of different concentrations of A and B on HepG2 cells and the combination of different
concentrations of A and B in the treatment of HepG2 cells. The results showed that different concentrations of A and B
alone treated HepG2 cells, the degree of inhibition of the performance of time-dose-dependent effect, and in A 6μmol
/ L combined B 100μmol / L synergistic effect is most significant. Flow cytometry showed that the apoptosis rate of
the combination group was more obvious. Western Blot assay showed that the expression of Bax and FADD increased
and the expression of anti-apoptotic protein Bcl-2 was decreased.


Full Text:

PDF


(23 Abstract Views, 11 PDF Downloads)

Refbacks

  • There are currently no refbacks.